Friday, 24 May, 2024
HomeMedico-LegalAstraZeneca sued over jab side effects

AstraZeneca sued over jab side effects

AstraZeneca is under legal fire from dozens of people over a side effect of its Covid-19 vaccine – a rare condition involving blood clots along with abnormally low platelet levels.

Lawyers have sent the company pre-action protocol letters, step one in a legal claim on behalf of around 75 claimants. Some have lost relatives and some have survived with catastrophic injuries after blood clots, reports The BMJ.

Many millions have had the vaccine without suffering complications but in 2021 the Medicines and Healthcare Products Regulatory Agency confirmed a possible link between the vaccine – Vaxzevria – the condition involving clots. Those taking legal action have been diagnosed with vaccine-induced thrombotic thrombocytopenia.

The British claimants are pursuing legal action under the Consumer Protection Act 1987 as well as claiming payment under the government-run Vaccine Damage Payment Scheme.

The scheme has paid out in several cases, but is limited to £120  000 per claim and applicants must prove severe disablement.

Payment under the scheme does not preclude a claim for personal injury through the courts. Those taking action under the Consumer Protection Act must show that the vaccine was not as safe as the public were entitled to expect.

Peter Todd, a consultant solicitor with Scott-Moncrieff & Associates, one of two lawyers handling claims, told The BMJ that the complications included stroke, heart failure and leg amputations. He said the technology involved in the AstraZeneca vaccine was “risky”.

Even though the legal claim is against AstraZeneca, the UK taxpayer will have to pay any compensation awarded, under a legal indemnity that the government gave the company early in the pandemic.

In response to a freedom of information request, NHS Business Services, which operates the vaccine damage scheme, revealed that by 6 March 2023 the scheme had received 4 017 claims relating to a Covid-19 vaccine.

Of those already dealt with, 622 concerned the AstraZeneca vaccine, 348 the Pfizer, and 43 the Moderna vaccine. Of the 4 017 claims, 334 were for deaths.

Sarah Moore, a partner in the Hausfeld law firm, whose clients are also taking legal action, said the maximum £120 000 payment from the scheme was “nothing” in cases where the person who was injured or died was a breadwinner. “Many were parents and many were caregivers,” she said.

Damages for individuals in the court action could be in the millions, she added. “We’ve been trying to get the government to reform its statutory scheme. We didn’t want to litigate but the government has forced us into a corner. The only way these families can get compensation is to fight the battle they didn’t want to fight.”

An AstraZeneca spokesperson said the company could not comment on ongoing legal matters, but added: “Patient safety is our highest priority and regulatory authorities have clear and stringent standards to ensure the safe use of all medicines, including vaccines. Our sympathy goes to anyone who has reported health problems.

“AstraZeneca and regulatory authorities carefully record and assess all reports of potential adverse events associated with use of Vaxzevria. From the body of evidence in clinical trials and real world data, Vaxzevria has continuously been shown to have an acceptable safety profile and regulators worldwide state that the benefits of vaccination outweigh the risks of extremely rare potential side effects.”


The BMJ article – Patients launch legal action against AstraZeneca over its covid-19 vaccine (Open access)


See more from MedicalBrief archives:


Cerebral venous thrombosis and the AstraZeneca vaccine — UK cohort study


Diverging national vaccination policies fuel public mistrust and hesitancy


India vaccine-maker destroys 100m expired COVID doses


Thrombosis and thrombocytopenia after ChAdOx1 nCoV-19 vaccination





MedicalBrief — our free weekly e-newsletter

We'd appreciate as much information as possible, however only an email address is required.